Retatrutide and Birth Control
The interaction between GLP-1 medications and oral birth control has become a significant concern since tirzepatide's label was updated with warnings about reduced contraceptive absorption. As a triple agonist with potent GLP-1 activity, retatrutide shares this concern. Additionally, weight loss itself can restore fertility in women with obesity-related anovulation, creating a "double fertility boost" that patients need to understand. Here is what the science says and what you should do (Jastreboff et al., NEJM 2023).
Medical Disclaimer: This article is for informational purposes only. Retatrutide is an investigational drug not yet approved by the FDA. Discuss contraception strategies with your healthcare provider before starting any GLP-1 medication. Unplanned pregnancy during GLP-1 therapy carries unknown risks.
How Retatrutide May Affect Oral Contraceptives
Oral birth control pills rely on consistent absorption of hormones (ethinyl estradiol and progestins) through the gastrointestinal tract. Retatrutide significantly slows gastric emptying through its GLP-1 receptor activation, which can delay and potentially reduce the absorption of oral medications, including contraceptive hormones.
The FDA required tirzepatide (Mounjaro/Zepbound) to include labeling about this interaction based on pharmacokinetic studies showing reduced oral contraceptive hormone levels. While specific studies with retatrutide have not been published, the same mechanism applies. The GLP-1-mediated delay in gastric emptying is a class effect shared by all GLP-1 receptor agonists, and retatrutide's potent GLP-1 activity suggests similar or greater impact.
Which Birth Control Methods Are Affected
| Method | Affected by Retatrutide? | Recommendation |
|---|---|---|
| Oral contraceptive pills | Yes - absorption may be reduced | Use backup method or switch |
| IUD (hormonal or copper) | No - not affected | Continue as normal |
| Implant (Nexplanon) | No - not affected | Continue as normal |
| Depo-Provera (injection) | No - not affected | Continue as normal |
| Patch (Xulane) | No - transdermal absorption | Continue as normal |
| Vaginal ring (NuvaRing) | No - vaginal absorption | Continue as normal |
| Condoms | No - barrier method | Continue as normal |
The Fertility Boost Effect
Beyond the absorption concern, there is a second critical issue: weight loss itself can dramatically restore fertility. Obesity is a leading cause of anovulation (failure to ovulate regularly) and is strongly linked to polycystic ovary syndrome (PCOS). When women with obesity lose 10-15% of body weight, ovulation often resumes, sometimes before menstrual cycles even normalize visually.
With retatrutide producing 20-24% weight loss, patients who were previously subfertile due to obesity may become significantly more fertile within months. This "Ozempic baby" phenomenon has been widely reported with semaglutide and tirzepatide. Retatrutide's more dramatic weight loss may make this fertility restoration even more pronounced.
Recommended Contraception Strategy
For women of childbearing potential starting retatrutide, the following approach is recommended:
- Best options: Non-oral methods (IUD, implant, Depo-Provera, patch, or ring) that bypass the GI tract entirely
- If continuing oral pills: Use a backup barrier method (condoms) during the first 4-8 weeks and after each dose escalation
- Consider switching: Talk to your OB/GYN about transitioning from oral contraceptives to a long-acting reversible contraception (LARC) method before starting retatrutide
- Timing for oral pills: If continuing oral contraceptives, take them at least 1 hour before or after any food, and consider taking them at a time when gastric emptying is least affected (such as first thing in the morning on an empty stomach)
If You Want to Get Pregnant
Retatrutide should be stopped well before conception. Based on class guidance for GLP-1 medications, providers typically recommend discontinuing retatrutide at least 2 months before trying to conceive. This washout period allows the drug to clear the body and gastric motility to normalize. There are no fertility benefits to being on retatrutide during conception, and the effects of GLP-1 medications on fetal development are not well studied.
GI Side Effects and Birth Control
Vomiting is an additional concern for oral contraceptive users. If vomiting occurs within 2 hours of taking a birth control pill, the hormones may not have been absorbed. GLP-1 medications can cause vomiting, particularly during dose escalation. Patients on oral contraceptives should use a backup method if vomiting occurs and follow their specific pill's missed-dose instructions.
GLP-1 Treatment With Comprehensive Care
Trimi offers compounded semaglutide ($99/month) and compounded tirzepatide ($125/month) with medical teams who address all medication interactions, including contraception. Learn how Trimi works.
Frequently Asked Questions
Will retatrutide make my birth control pill less effective?
Potentially yes. Delayed gastric emptying can reduce oral contraceptive absorption. Consider using a non-oral method or adding a backup barrier method during retatrutide treatment.
Is the IUD the best option while on retatrutide?
IUDs (both hormonal and copper) are excellent choices because they are not affected by gastric emptying changes. Implants and injections are also unaffected. Any non-oral method eliminates the absorption concern.
Can retatrutide increase fertility?
Indirectly, yes. Weight loss from retatrutide can restore ovulation in women with obesity-related anovulation or PCOS. This fertility restoration can happen quickly, sometimes within the first few months of treatment.
How long should I stop retatrutide before trying to conceive?
Most providers recommend stopping GLP-1 medications at least 2 months before planned conception. Discuss your specific timeline with your healthcare provider.
More on Retatrutide
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).